A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

NCT06703021 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity
Overweight
Chronic Weight Management

Interventions

DRUG: aleniglipron or placebo
DRUG: aleniglipron or placebo
DRUG: aleniglipron or placebo
DRUG: aleniglipron or placebo

Sponsor

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics